Nalmefene

Red

Brand Name(s):Selincro

Indication:Alcohol disorders

Rationale:1,2,8

Considered:Jan-13

Review Date:Jan-20

Comments:
NICE TA325

1.1 Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for people with alcohol dependence:

* who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the World Health Organization’s drinking risk levels) without physical withdrawal symptoms and

* who do not require immediate detoxification.

The marketing authorisation states that nalmefene should:

* only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption and

* be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.

http://www.nice.org.uk/guidance/ta325/chapter/1-guidance

November 2014